- New facility is first part of Massachusetts capacity expansion
- Build completed in less than five months to meet unprecedented demand for Cytiva technologies and solutions
- Hiring approximately 200 people in Massachusetts
December 21, 2020
Cytiva, a global life sciences leader, has opened its new 80,000 square foot manufacturing facility in Shrewsbury, Massachusetts. This is one of the first major accomplishments in Cytiva’s USD 500-million global capacity expansion over the next five years. The Shrewsbury site has also benefited from the support of a Technology Investment Agreement entered in October with the Biomedical Advanced Research and Development Authority (BARDA).
Xcellerex XDR bioreactors, which provide the flexible and scalable solutions drug developers needing to manufacture biopharmaceuticals, vaccines and antibodies, will be made at the new facility. It is the latest addition to a global manufacturing and distribution network that spans North America, Europe, and Asia.
Mary Blenn, Vice President, Global Supply Chain, says: “The new Shrewsbury site is a primary example of our work to advance and accelerate therapeutics. Our team has worked tirelessly for the last five months to safely complete this new facility, so that our customers can continue researching, developing, and manufacturing next generation therapeutics that will transform global health.”
With five manufacturing lines operating 24/5, a new clean room, and a research and development lab, the Shrewsbury facility will enable Cytiva to better respond to increased demand and new market opportunities. It also frees up capacity in the Westborough facility to add manufacturing lines for complementary single-use technologies. Cytiva expects to complete its Westborough capacity expansion by Q2 2021.
Filling the site with talented people is also a key component of Cytiva’s expansion strategy. Over the next several months, the company plans hire approximately 200 Massachusetts-based associates for diverse roles.
Before the COVID-19 pandemic, the biotherapeutics industry was predicted to experience double-digit growth year-on-year between now and 20251. In 2019, more than 75 percent of the biological therapies approved by the United States Food and Drug Administration relied on Cytiva’s technologies for manufacturing.
To watch a playback of our broadcast of the opening of the Shrewsbury facility please click here.
1BioPlan's 2020 Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, p 29
Cytiva is a global life sciences leader with more than 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
+1 774 245 3893